ZyVersa Therapeutics annual depreciation and amortization
2022
2022
2023
2024
2025
ZyVersa Therapeutics Depreciation & Amortization Growth & History (ZVSA)
ZyVersa Therapeutics's depreciation and amortization was $0 for fiscal 2025.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$6,933 | — |
| 2024 | 2024-12-31 | $6,933 | −$3,467 | −33.34% |
| 2023 | 2023-12-31 | $10,400 | — | — |
| 2022 | 2022-12-31 | $9,868 | — | — |
| 2022 | 2022-12-12 | $9,868 | — | — |
ZyVersa Therapeutics quarterly depreciation and amortization
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $0 | −$1,733 | — |
| Q2 2025 | 2025-06-30 | $0 | −$2,600 | — |
| Q1 2025 | 2025-03-31 | $0 | −$2,600 | — |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $1,733 | −$867 | −33.35% |
| Q2 2024 | 2024-06-30 | $2,600 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $2,600 | $0 | 0.00% |
| Q3 2023 | 2023-09-30 | $2,600 | — | — |
| Q2 2023 | 2023-06-30 | $2,600 | — | — |
| Q1 2023 | 2023-03-31 | $2,600 | — | — |
ZyVersa Therapeutics depreciation and amortization trends
Between the periods ended 2022-12-12 and 2025-12-31, ZyVersa Therapeutics's depreciation and amortization decreased from $9,868 to $0, a change of −$9,868. The latest reported quarter, Q4 2025, shows $0.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗